ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

Prescriber Checkup » North Carolina » Hematology Oncology

Top Hematology Oncology Prescribers in North Carolina

Top Prescribers

Providers are grouped by the primary specialty they listed when applying for a national health ID number. This doesn’t necessarily mean the person has special training or certification. Specialty is self-reported by providers and may have changed. Patients and claims shown are for Medicare Part D only.

Prescriber Claims Filled Total Cost Medicare Part D Patients Claims for Brand Name Drugs Schedule Two Schedule Three Dangerous Drugs to Seniors Brand Name Drugs Prescription Price
FRANCISCO CASTILLOS MD

Hematology Oncology

6,546

$871K

340
211 are 65+

8%
patients receiving schedule two controlled substances

Avg: 19%

12%
patients receiving schedule three controlled substances

Avg: 8%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

30%
prescriptions for brand name drugs

Avg: 18%

$133
Average prescription price

Avg: $415

JAMES ATKINS M.D.

Hematology Oncology

4,842

$999K

373
258 are 65+

24%
patients receiving schedule two controlled substances

Avg: 19%

21%
patients receiving schedule three controlled substances

Avg: 8%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

28%
prescriptions for brand name drugs

Avg: 18%

$206
Average prescription price

Avg: $415

RUSSELL ANDERSON

Hematology Oncology

3,657

$908K

344
234 are 65+

27%
patients receiving schedule two controlled substances

Avg: 19%

14%
patients receiving schedule three controlled substances

Avg: 8%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

19%
prescriptions for brand name drugs

Avg: 18%

$248
Average prescription price

Avg: $415

HEATHER WHITE MD

Hematology Oncology

2,556

$546K

305
250 are 65+

13%
patients receiving schedule two controlled substances

Avg: 19%

12%
patients receiving schedule three controlled substances

Avg: 8%

3%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

14%
prescriptions for brand name drugs

Avg: 18%

$214
Average prescription price

Avg: $415

RICHARD ORLOWSKI MD

Hematology Oncology

2,522

$737K

494
377 are 65+

12%
patients receiving schedule two controlled substances

Avg: 19%

13%
patients receiving schedule three controlled substances

Avg: 8%

4%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

12%
prescriptions for brand name drugs

Avg: 18%

$292
Average prescription price

Avg: $415

SUSAN WILLIFORD MD

Hematology Oncology

2,274

$555K

233
188 are 65+

9%
patients receiving schedule two controlled substances

Avg: 19%

10%
patients receiving schedule three controlled substances

Avg: 8%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

17%
prescriptions for brand name drugs

Avg: 18%

$244
Average prescription price

Avg: $415

JANAK CHOKSI MD

Hematology Oncology

2,114

$527K

259
226 are 65+

13%
patients receiving schedule two controlled substances

Avg: 19%

12%
patients receiving schedule three controlled substances

Avg: 8%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

17%
prescriptions for brand name drugs

Avg: 18%

$249
Average prescription price

Avg: $415

SAMER KASBARI MD, MS

Hematology Oncology

2,029

$494K

281
200 are 65+

29%
patients receiving schedule two controlled substances

Avg: 19%

11%
patients receiving schedule three controlled substances

Avg: 8%

9%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

16%
prescriptions for brand name drugs

Avg: 18%

$243
Average prescription price

Avg: $415

DEBRA MILLER MD

Hematology Oncology

1,816

$390K

236
175 are 65+

17%
patients receiving schedule two controlled substances

Avg: 19%

14%
patients receiving schedule three controlled substances

Avg: 8%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

15%
prescriptions for brand name drugs

Avg: 18%

$215
Average prescription price

Avg: $415

KENNETH KARB M.D.

Hematology Oncology

1,801

$362K

183
133 are 65+

26%
patients receiving schedule two controlled substances

Avg: 19%

20%
patients receiving schedule three controlled substances

Avg: 8%

5%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

13%
prescriptions for brand name drugs

Avg: 18%

$201
Average prescription price

Avg: $415

WILLIAM BUTLER MD

Hematology Oncology

1,793

$742K

234
157 are 65+

25%
patients receiving schedule two controlled substances

Avg: 19%

18%
patients receiving schedule three controlled substances

Avg: 8%

3%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

23%
prescriptions for brand name drugs

Avg: 18%

$414
Average prescription price

Avg: $415

PAM SHOLAR MD

Hematology Oncology

1,790

$250K

237
195 are 65+

11%
patients receiving schedule two controlled substances

Avg: 19%

17%
patients receiving schedule three controlled substances

Avg: 8%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

13%
prescriptions for brand name drugs

Avg: 18%

$140
Average prescription price

Avg: $415

JESSE LEE MD

Hematology Oncology

1,782

$1.37M

226
184 are 65+

22%
patients receiving schedule two controlled substances

Avg: 19%

13%
patients receiving schedule three controlled substances

Avg: 8%

3%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

23%
prescriptions for brand name drugs

Avg: 18%

$770
Average prescription price

Avg: $415

MISBAH QADIR MD

Hematology Oncology

1,761

$701K

187
139 are 65+

20%
patients receiving schedule two controlled substances

Avg: 19%

0%
patients receiving schedule three controlled substances

Avg: 8%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

18%
prescriptions for brand name drugs

Avg: 18%

$398
Average prescription price

Avg: $415

JAMES RADFORD MD

Hematology Oncology

1,741

$697K

219
183 are 65+

18%
patients receiving schedule two controlled substances

Avg: 19%

0%
patients receiving schedule three controlled substances

Avg: 8%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

19%
prescriptions for brand name drugs

Avg: 18%

$401
Average prescription price

Avg: $415

KELVIN RAYBON M.D.

Hematology Oncology

1,733

$1.25M

158
107 are 65+

16%
patients receiving schedule two controlled substances

Avg: 19%

19%
patients receiving schedule three controlled substances

Avg: 8%

3%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

19%
prescriptions for brand name drugs

Avg: 18%

$720
Average prescription price

Avg: $415

ELLEN WILLARD MD

Hematology Oncology

1,704

$724K

260
214 are 65+

15%
patients receiving schedule two controlled substances

Avg: 19%

6%
patients receiving schedule three controlled substances

Avg: 8%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

18%
prescriptions for brand name drugs

Avg: 18%

$425
Average prescription price

Avg: $415

JOHN HUFFMAN MD

Hematology Oncology

1,697

$249K

181
156 are 65+

12%
patients receiving schedule two controlled substances

Avg: 19%

13%
patients receiving schedule three controlled substances

Avg: 8%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

17%
prescriptions for brand name drugs

Avg: 18%

$146
Average prescription price

Avg: $415

PETER MANCUSI-UNGARO MD

Hematology Oncology

1,648

$2.26M

166
114 are 65+

24%
patients receiving schedule two controlled substances

Avg: 19%

0%
patients receiving schedule three controlled substances

Avg: 8%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

28%
prescriptions for brand name drugs

Avg: 18%

$1369
Average prescription price

Avg: $415

JOHN INZERILLO M.D.

Hematology Oncology

1,609

$647K

197
145 are 65+

28%
patients receiving schedule two controlled substances

Avg: 19%

16%
patients receiving schedule three controlled substances

Avg: 8%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

20%
prescriptions for brand name drugs

Avg: 18%

$402
Average prescription price

Avg: $415

MARK YOFFE M.D.

Hematology Oncology

1,510

$363K

190
142 are 65+

21%
patients receiving schedule two controlled substances

Avg: 19%

11%
patients receiving schedule three controlled substances

Avg: 8%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

21%
prescriptions for brand name drugs

Avg: 18%

$240
Average prescription price

Avg: $415

MATTHEW REES M.D.

Hematology Oncology

1,384

$222K

262
185 are 65+

11%
patients receiving schedule two controlled substances

Avg: 19%

7%
patients receiving schedule three controlled substances

Avg: 8%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

14%
prescriptions for brand name drugs

Avg: 18%

$160
Average prescription price

Avg: $415

KEITH LERRO M.D.

Hematology Oncology

1,381

$738K

207
145 are 65+

24%
patients receiving schedule two controlled substances

Avg: 19%

12%
patients receiving schedule three controlled substances

Avg: 8%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

14%
prescriptions for brand name drugs

Avg: 18%

$535
Average prescription price

Avg: $415

I-WEN CHANG M.D.

Hematology Oncology

1,379

$425K

253
183 are 65+

27%
patients receiving schedule two controlled substances

Avg: 19%

14%
patients receiving schedule three controlled substances

Avg: 8%

5%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

17%
prescriptions for brand name drugs

Avg: 18%

$308
Average prescription price

Avg: $415

TODD MOORE MD

Hematology Oncology

1,371

$778K

164
127 are 65+

34%
patients receiving schedule two controlled substances

Avg: 19%

10%
patients receiving schedule three controlled substances

Avg: 8%

4%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

20%
prescriptions for brand name drugs

Avg: 18%

$568
Average prescription price

Avg: $415

Sources

Centers for Medicare and Medicaid Services; National Technical Information Service; First Databank